Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of izokibep (ABY-035) in active psoriatic arthritis
2019-003405-94Phase 2Completed
- Sponsor
- Acelyrin
- Start
- Nov 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of izokibep in psoriatic arthritis (PsA) (3 arms), sponsored by Acelyrin. Started Nov 2019; status: completed.
02
Drugs
izokibep
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2019-003405-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003405-94.